mRNA vaccines work by delivering a small piece of genetic instruction into your cells, telling them to build a harmless protein found on the surface of a virus. Your immune system spots that protein, recognizes it as foreign, and mounts a defense, training itself to fight the real virus if you ever encounter it. The whole process happens without exposing you to any actual virus.
The Instructions Get In
mRNA on its own is fragile. If injected into your body unprotected, enzymes in your blood would shred it within minutes. To solve this, the mRNA is wrapped in a tiny fat bubble called a lipid nanoparticle. These particles are made of four types of lipids plus cholesterol, forming a shell roughly a thousand times smaller than the width of a human hair. Once injected into your arm, the lipid nanoparticles fuse with your cell membranes and release their mRNA cargo inside.
This protective shell works well. Research published in ACS Nano found that mRNA circulating in blood at body temperature had a half-life of nearly five days while still enclosed in lipid nanoparticles, meaning the packaging keeps the instructions intact long enough to reach cells and do their job.
Your Cells Build the Protein
Once inside a cell, the mRNA never enters the nucleus where your DNA is stored. It stays in the cytoplasm, the general workspace of the cell. There, structures called ribosomes read the mRNA like a set of blueprints, stringing together amino acids in the exact sequence needed to form a specific protein. In the case of COVID-19 vaccines, that protein is the spike protein, the distinctive structure that coats the surface of the SARS-CoV-2 virus and allows it to latch onto human cells.
Your cells display copies of this spike protein on their surface, essentially waving a flag that says “something unfamiliar is here.” The mRNA itself is broken down by the cell within a few days, just as your body routinely breaks down its own natural mRNA after proteins have been made. The spike proteins persist a bit longer, lasting up to a few weeks before being cleared, similar to the lifespan of other proteins your body produces.
How Your Immune System Responds
The spike proteins trigger a coordinated two-pronged attack from your immune system. The first prong involves B cells, which produce antibodies. These antibodies are custom-shaped to latch onto the spike protein and neutralize it. Spike-specific B cells appear in circulation about two weeks after a full vaccination course, and booster doses increase levels of a particular antibody type called IgA, which is especially useful at mucosal surfaces like the nose and throat.
The second prong involves T cells, which handle threats that antibodies can’t reach. Helper T cells (CD4+ cells) activate early and play a coordinating role, helping B cells mature and ramping up the broader immune response. They release signaling molecules that steer the immune system toward an effective antiviral posture. Killer T cells (CD8+ cells) also expand after vaccination, though their response is more variable between individuals. These cells are trained to destroy any of your own cells that become infected with the actual virus, stopping it from replicating.
This layered defense is what makes the protection durable. Even when antibody levels decline over time, memory B cells and T cells remain in the body, ready to mount a rapid response if the real virus appears. Research from JCI Insight found that after vaccination, CD4+ T cells could be detected producing multiple immune signals simultaneously, a sign of a robust, “polyfunctional” response capable of contributing to long-term recall.
Why mRNA Cannot Change Your DNA
Your DNA lives inside the cell nucleus, behind a separate membrane. mRNA from a vaccine never crosses that barrier. It does its work entirely in the cytoplasm, and your cells lack the molecular machinery needed to convert mRNA back into DNA and splice it into your genome. This is a one-way street: DNA normally produces mRNA, not the other way around. The synthetic mRNA in the vaccine is read, used, and then broken down by the same enzymes that dispose of your body’s own mRNA every day.
Decades of Research Behind the Technology
mRNA vaccines may have seemed to appear overnight during the COVID-19 pandemic, but the underlying science stretches back more than 30 years. Scientists first discovered mRNA and its role in protein production between the 1960s and 1990s. A critical breakthrough came in 2005, when researchers showed that chemically modified mRNA could be delivered into cells without triggering a dangerous overreaction from the immune system. That discovery removed one of the biggest roadblocks to using mRNA as medicine.
Between 2005 and 2016, scientists developed lipid nanoparticles as delivery vehicles, solving the fragility problem. In parallel, NIH researchers figured out how to stabilize the spike proteins of various coronaviruses, including a common-cold coronavirus in 2016 and the MERS coronavirus in 2017. By 2016, NIH and Moderna had begun collaborating on a general mRNA vaccine design that could be rapidly adapted to emerging viruses. When the genetic sequence of SARS-CoV-2 was published in January 2020, researchers essentially swapped in the new spike protein sequence and had a vaccine candidate ready for clinical trials within weeks.
How mRNA Vaccines Differ From Traditional Vaccines
Traditional vaccines typically use a weakened or inactivated version of a virus, or a piece of it grown in eggs or cell cultures. This process can take months, sometimes over a year, to scale up. mRNA vaccines skip all of that. Instead of growing biological material, manufacturers synthesize the mRNA sequence in a lab, a process closer to printing code than farming cells.
This gives mRNA a major speed advantage. Once the platform exists, updating it for a new variant or an entirely different pathogen is as simple as changing the genetic sequence, like swapping a new face onto an existing wanted poster template. The manufacturing infrastructure stays the same. That flexibility proved essential during the pandemic and is now being directed at a much wider range of diseases.
Beyond COVID-19
The same mRNA platform is being tested against cancers, influenza, RSV, and other infectious diseases. In oncology, the approach gets a personalized twist: researchers sequence a patient’s tumor, identify proteins unique to their cancer cells, and encode those proteins into a custom mRNA vaccine that trains the immune system to hunt down the tumor.
One such personalized cancer vaccine showed promising results in a phase 2 trial for melanoma patients who had their tumors surgically removed. When combined with an immunotherapy drug, 83% of patients remained cancer-free at 12 months, compared with 79% on the immunotherapy alone. That vaccine is now in a phase 3 trial across 26 countries. Broader programs are fast-tracking thousands of patients into mRNA trials targeting lung, breast, and head and neck cancers, marking the technology’s expansion well beyond the pandemic that brought it to public attention.